share_log

Adial Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Officer Truluck Joseph

Adial Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities

Adial Pharmaceuticals | 4：持股變動聲明
美股SEC公告 ·  03/27 18:10

Moomoo AI 已提取核心訊息

Joseph Truluck, the Chief Financial Officer of Adial Pharmaceuticals, Inc. (ADIL), was involved in a transaction on March 25, 2024. The specific details of the transaction, including the action type, status, number of shares involved, nature of the shares, transaction price, and the total value of shares, were not disclosed in the announcement. The report also did not provide information on the number of shares held by Truluck after the transaction. Investors are advised to seek additional information to fully understand the impact of this event on their investment decisions.
Joseph Truluck, the Chief Financial Officer of Adial Pharmaceuticals, Inc. (ADIL), was involved in a transaction on March 25, 2024. The specific details of the transaction, including the action type, status, number of shares involved, nature of the shares, transaction price, and the total value of shares, were not disclosed in the announcement. The report also did not provide information on the number of shares held by Truluck after the transaction. Investors are advised to seek additional information to fully understand the impact of this event on their investment decisions.
阿迪爾製藥公司（ADIL）首席財務官約瑟夫·特魯魯克於2024年3月25日參與了一筆交易。公告中未披露該交易的具體細節，包括行動類型、狀態、所涉股票數量、股票性質、交易價格和股票總價值。該報告也沒有提供有關Truluck在交易後持有的股票數量的信息。建議投資者尋求更多信息，以充分了解這一事件對其投資決策的影響。
阿迪爾製藥公司（ADIL）首席財務官約瑟夫·特魯魯克於2024年3月25日參與了一筆交易。公告中未披露該交易的具體細節，包括行動類型、狀態、所涉股票數量、股票性質、交易價格和股票總價值。該報告也沒有提供有關Truluck在交易後持有的股票數量的信息。建議投資者尋求更多信息，以充分了解這一事件對其投資決策的影響。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    熱議
    美股
    股票代碼最新價升跌幅

    暫無數據

    資訊熱榜
    更新時間